Asundexian versus Apixaban in Patients with Atrial Fibrillation
Most Cited Paper
in Atrial Fibrillation Management and Outcomes
18 Months Post-Publication
Class of 2026
“Asundexian versus Apixaban in Patients with Atrial Fibrillation”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026/
Topics
Factor XI inhibition · Apixaban · Factor XI inhibition · Direct oral anticoagulants · atrial fibrillation · Stroke prevention · Thromboembolic events · Major bleeding · CHA2DS2-VASc score · Noninferiority trial · Early trial termination · Data and safety monitoring board · OCEANIC-AF trial · phase 3 trial · Factor XI inhibition · Hazard ratio · Bleeding risk assessment
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Atrial Fibrillation Management and Outcomes Papers, Class of 2026. https://pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459